Literature DB >> 23558524

Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.

J C Strefford1, L-A Sutton, P Baliakas, A Agathangelidis, J Malčíková, K Plevova, L Scarfó, Z Davis, E Stalika, D Cortese, N Cahill, L B Pedersen, P F di Celle, T Tzenou, C Geisler, P Panagiotidis, A W Langerak, N Chiorazzi, S Pospisilova, D Oscier, F Davi, C Belessi, L Mansouri, P Ghia, K Stamatopoulos, R Rosenquist.   

Abstract

Recent studies have revealed recurrent mutations of the NOTCH1, SF3B1 and BIRC3 genes in chronic lymphocytic leukemia (CLL), especially among aggressive, chemorefractory cases. Nevertheless, it is currently unknown whether their presence may differ in subsets of patients carrying stereotyped B-cell receptors and also exhibiting distinct prognoses. Here, we analyzed the mutation status of NOTCH1, SF3B1 and BIRC3 in three subsets with particularly poor prognosis, that is, subset #1, #2 and #8, aiming to explore links between genetic aberrations and immune signaling. A remarkably higher frequency of SF3B1 mutations was revealed in subset #2 (44%) versus subset #1 and #8 (4.6% and 0%, respectively; P<0.001). In contrast, the frequency of NOTCH1 mutations in subset #2 was only 8%, lower than the frequency observed in either subset #1 or #8 (19% and 14%, respectively; P=0.04 for subset #1 versus #2). No associations were found for BIRC3 mutations that overall were rare. The apparent non-random association of certain mutations with stereotyped CLL subsets alludes to subset-biased acquisition of genomic aberrations, perhaps consistent with particular antigen/antibody interactions. These novel findings assist in unraveling specific mechanisms underlying clinical aggressiveness in poor-prognostic stereotyped subsets, with far-reaching implications for understanding their clonal evolution and implementing biologically oriented therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23558524     DOI: 10.1038/leu.2013.98

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  40 in total

1.  A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact.

Authors:  A C Queirós; N Villamor; G Clot; A Martinez-Trillos; M Kulis; A Navarro; E M M Penas; S Jayne; A Majid; J Richter; A K Bergmann; J Kolarova; C Royo; N Russiñol; G Castellano; M Pinyol; S Bea; I Salaverria; M López-Guerra; D Colomer; M Aymerich; M Rozman; J Delgado; E Giné; M González-Díaz; X S Puente; R Siebert; M J S Dyer; C López-Otín; C Rozman; E Campo; A López-Guillermo; J I Martín-Subero
Journal:  Leukemia       Date:  2014-08-25       Impact factor: 11.528

2.  Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia.

Authors:  L Mansouri; L-A Sutton; V Ljungström; E F Sörqvist; R Gunnarsson; K E Smedby; G Juliusson; K Stamatopoulos; M Nilsson; R Rosenquist
Journal:  Leukemia       Date:  2013-10-31       Impact factor: 11.528

3.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

4.  On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.

Authors:  D Cortese; L-A Sutton; N Cahill; K E Smedby; C Geisler; R Gunnarsson; G Juliusson; L Mansouri; R Rosenquist
Journal:  Leukemia       Date:  2013-11-12       Impact factor: 11.528

5.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

6.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

Authors:  Lesley-Ann Sutton; Viktor Ljungström; Larry Mansouri; Emma Young; Diego Cortese; Veronika Navrkalova; Jitka Malcikova; Alice F Muggen; Martin Trbusek; Panagiotis Panagiotidis; Frederic Davi; Chrysoula Belessi; Anton W Langerak; Paolo Ghia; Sarka Pospisilova; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

Review 7.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

8.  Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Authors:  Elisa ten Hacken; Maria Gounari; Jaap Willem Back; Ekaterina Shimanovskaya; Lydia Scarfò; Ekaterina Kim; Jared Burks; Maurilio Ponzoni; Giuseppe Alvise Ramirez; William G Wierda; Zeev Estrov; Michael J Keating; Alessandra Ferrajoli; Kostas Stamatopoulos; Paolo Ghia; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

9.  Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Authors:  Panagiotis Baliakas; Andreas Agathangelidis; Anastasia Hadzidimitriou; Lesley-Ann Sutton; Eva Minga; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao-Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles C Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin E Smedby; Lone Bredo Pedersen; Denis Moreno; Kirsten Van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie-Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian H Geisler; Anton W Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane F Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113

10.  Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Authors:  Lesley-Ann Sutton; Emma Young; Panagiotis Baliakas; Anastasia Hadzidimitriou; Theodoros Moysiadis; Karla Plevova; Davide Rossi; Jana Kminkova; Evangelia Stalika; Lone Bredo Pedersen; Jitka Malcikova; Andreas Agathangelidis; Zadie Davis; Larry Mansouri; Lydia Scarfò; Myriam Boudjoghra; Alba Navarro; Alice F Muggen; Xiao-Jie Yan; Florence Nguyen-Khac; Marta Larrayoz; Panagiotis Panagiotidis; Nicholas Chiorazzi; Carsten Utoft Niemann; Chrysoula Belessi; Elias Campo; Jonathan C Strefford; Anton W Langerak; David Oscier; Gianluca Gaidano; Sarka Pospisilova; Frederic Davi; Paolo Ghia; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.